GeneOne Life Science, Inc.: debt-to-equity, ROE and more
KOSPI, Legal name GeneOne Life Science, Inc.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 191.5%
- Equity ratio
- 34.3%
- ROE
- -126.8%
- Op. margin
- -191.1%
- Rev. growth
- -35.5%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is below paid-in capital: partial impairment (자본잠식), rate 52.1%.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 21.4% | 82.3% | -7.8% | -71.1% | n/a |
| FY2022 consolidated | 22.8% | 81.4% | -21.0% | -82.3% | 25.9% |
| FY2023 consolidated | 35.4% | 73.8% | -69.8% | -120.3% | -17.5% |
| FY2024 consolidated | 76.8% | 56.6% | -56.7% | -120.5% | -11.2% |
| FY2025 consolidated | 191.5% | 34.3% | -126.8% | -191.1% | -35.5% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩38.7B | ₩48.7B | ₩40.2B | ₩35.7B | ₩23.0B |
| Operating profit | -₩27.5B | -₩40.1B | -₩48.4B | -₩43.0B | -₩44.0B |
| Pre-tax income | -₩15.6B | -₩38.1B | -₩77.7B | -₩48.8B | -₩51.9B |
| Net income | -₩16.0B | -₩38.2B | -₩77.8B | -₩48.5B | -₩51.9B |
| Total assets | ₩249.5B | ₩222.9B | ₩151.0B | ₩151.3B | ₩119.2B |
| Total liabilities | ₩44.0B | ₩41.4B | ₩39.5B | ₩65.7B | ₩78.3B |
| Total equity | ₩205.5B | ₩181.5B | ₩111.5B | ₩85.6B | ₩40.9B |
| Paid-in capital | ₩77.5B | ₩77.8B | ₩78.5B | ₩80.0B | ₩85.4B |
| Debt/equity (source value) | 21.4% | 22.8% | 35.4% | 76.8% | 191.5% |
Company outline (FSC)
- Market
- KOSPI
- Fiscal year end
- Dec
- Founded
- 1976-01-27
- Listed
- 87/11/16
- Employees
- 52
- Auditor
- 대주회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101110191562
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 진원생명과학Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.